CompletedInterventional

Antiretroviral research for Watoto

The Watoto study is exploring how best to care for children and young people living with HIV who are starting anti-HIV treatment (known as antiretroviral therapy, or ART) for the first time. The study investigates two important questions. First, it compares whether tracking a child's health through routine clinic visits and physical symptoms works just as well and safely as having frequent, complex blood tests. Second, it tests whether starting treatment with an extra medicine for a short time before switching to standard therapy is better than staying on standard medicines throughout. Around 1,200 children aged between 6 months and 17 years take part. By comparing these approaches, researchers hope to find safe, practical, and effective ways to manage HIV in places where advanced laboratory equipment may not always be easily available.

At a glance

Status

Completed

Sponsor

Medical Research Council (UK)

Enrolment target

1,200

Start

02 Oct 2006

Estimated completion

14 Mar 2012

Human immunodeficiency virus

What is this study about?

HIV is a virus that weakens the immune system, which is the body's natural defence against illness. Modern anti-HIV medicines, known as antiretroviral therapy (or ART), work very well to keep the virus under control. When children take these medicines every day, they can grow up living healthy, active, and full lives. However, doctors are still working to find the simplest and most effective ways to prescribe and monitor these treatments in young people.

The Watoto study (named after the Swahili word for 'children') looks closely at how doctors keep track of a child's health while on treatment. In well-equipped hospitals, doctors often rely on frequent blood tests, such as CD4 counts, alongside physical check-ups. This study tests whether monitoring a child's health based mainly on routine clinic exams is just as safe as doing repeated, complex blood tests. This could make care far easier to deliver in communities where laboratories are scarce or expensive.

The study also compares two different ways of taking the medicines. One group takes a standard combination of medicines every day. Another group begins with an extra medicine for a short time to quickly suppress the virus, before stepping down to a simpler daily maintenance plan. Learning which method works better helps doctors give children the best possible start to treatment with the fewest side effects.

Key takeaways

The Watoto study tests the best ways to start and monitor HIV treatment in children and teenagers.
It compares regular clinic health checks against frequent routine blood tests.
It also looks at whether an intensive starter treatment works better than standard continuous therapy.
All children taking part receive proven, active anti-HIV medicines.
Participation is completely voluntary, and families can leave the study at any time.

Who may be eligible?

This study is designed for children and young people aged between 6 months and 17 years who have been diagnosed with HIV-1. To be eligible, the child must be ready to start anti-HIV treatment according to standard health guidelines, and they must not have taken long-term HIV medicines in the past.

Because caring for a child requires teamwork, each child must live with an adult carer who can support them. This carer might be receiving HIV treatment themselves, living with HIV, or HIV-negative, but they must be able to help the child attend appointments and take their medicine regularly.

The study is not suitable for children who have a sudden, severe infection that needs separate treatment, or those receiving chemotherapy for cancer. It is also not open to young people who are pregnant, breastfeeding, or taking other medicines that cannot safely be mixed with HIV treatment.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Child is aged between 6 months and 17 years
Child has a confirmed diagnosis of HIV-1
Child has never taken long-term anti-HIV medicines before
Child has an adult carer at home who can help with visits and medicines
Child is not currently pregnant or breastfeeding

Answer every question to see your result.

What does participation involve?

If a child joins the study, they will be given effective anti-HIV medications to take every day. A computer system will assign them by chance (like flipping a coin) to two different study groups. One decision determines whether their health is monitored using regular physical exams alone or physical exams combined with routine laboratory blood tests. The second decision determines whether they take standard continuous medicines or an intensive starter combination that switches to a maintenance routine later.

Families will attend scheduled appointments at the study clinic over several years. During these visits, doctors and nurses will check the child's height, weight, development, and general health. Carers will receive plenty of support and guidance on helping their child take their daily doses. If any child becomes unwell at any point, the medical team is always available to examine them and provide extra care.

Potential risks and benefits

Taking part ensures that a child receives close medical attention from an experienced clinical team, which helps keep their HIV well-managed. However, like all medications, anti-HIV drugs can sometimes cause side effects such as mild tummy upsets, tiredness, or skin rashes. Blood tests may also cause brief stinging or bruising. There is also a chance that one monitoring or treatment plan works slightly better than another, though safety is watched very closely throughout. Joining the trial is entirely voluntary, and families can choose to leave at any time without losing access to standard medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Clinical Trials Unit, Medical Research Council
City only
London, England

Common questions

What does the word 'Watoto' mean?

'Watoto' is the Swahili word for 'children'. The trial was named to reflect its focus on improving health outcomes for young people living with HIV.

Will my child definitely receive medicine for HIV?

Yes. Every child in this trial receives active, life-saving anti-HIV medicines. No child is given a dummy pill or left without treatment.

Why are some children not having routine blood tests?

In many parts of the world, specialised blood testing machines are rare or broken. The study is testing whether regular, careful physical check-ups by a doctor are just as safe and effective, so high-quality care can be provided anywhere.

Can my child have a blood test if they get sick?

Yes. Even if a child is in the clinic-monitoring group, doctors can still order any urgent blood tests needed if the child feels unwell or if there are concerns about their health.

Can we choose which group our child joins?

No. A computer assigns the groups by chance. This process is called randomisation, and it is the fairest scientific way to compare the different approaches without bias.

How to find out more

Diana Gibb

d.gibb@ctu.mrc.ac.uk +44 (0)20 7670 4709 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.